Sarepta Therapeutics (SRPT) Stock Price, Quote & News

Company Profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dyst...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 274 4000

Website: www.sarepta.com

Address:

215 First Street, Suite 415, Cambridge, United States

Fred_Sigma_Invest Jun. 24 at 4:48 PM

$SRPT

0 · Reply

Hoganknowsbest Jun. 24 at 4:42 PM

$SRPT need news to move it.

0 · Reply

Pipipopopipi Jun. 24 at 3:47 PM

$SRPT she’s holding extremely well. showing a lot of strength. Someone knows something😂😂😂😂

0 · Reply

Find_the_Cure Jun. 24 at 3:43 PM

$SRPT lunchtime manipulation because they can. Doug lets them.

0 · Reply

Find_the_Cure Jun. 24 at 2:41 PM

$SRPT bones: “he’s dead Jim”

0 · Reply

Fred_Sigma_Invest Jun. 24 at 2:40 PM

$SRPT You know it’s bad when not even @Thaigrlsrk is here pushing his lying, clownish BS.

1 · Reply

Pipipopopipi Jun. 24 at 2:30 PM

$SRPT markets moving up againg and srpt dives again. What a stock. in doug we trust. Easiest short on the market

0 · Reply

reggie_one Jun. 24 at 2:11 PM

$SRPT Up a few cents and the pumpers are all giddy thinking this will make them kazillionares following kims promises of 600 per share by end of year

0 · Reply

WeAreKangz Jun. 24 at 1:46 PM

$SRPT biotech higher highs sarepta lower lows lmao. Doug gets the short bus award of the year

1 · Reply

free2dream Jun. 24 at 1:36 PM

$SRPT WAKE THE FXCK UP WALL STREET ANALYST MORONS !

0 · Reply

Sarepta Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 4, 2026, 10:00 AM EDT - 20 days ago

Sarepta Therapeutics Transcript: AGM 2026

Jun 1, 2026, 4:30 PM EDT - 22 days ago

Sarepta Therapeutics to Participate in Upcoming Investor Conferences

2026-05-15T12:30:23.000Z - 5 weeks ago

Sarepta price target lowered to $19 from $20 at Evercore ISI

May 13, 2026, 4:30 PM EDT - 5 weeks ago

Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

2026-05-07T00:41:58.000Z - 6 weeks ago

Sarepta reports Q1 adjusted EPS $3.16 vs ($3.42) last year

May 6, 2026, 4:30 PM EDT - 6 weeks ago

Sarepta Therapeutics Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 6 weeks ago

Sarepta Therapeutics Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 6 weeks ago

Sarepta Therapeutics Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 6 weeks ago

Sarepta Therapeutics Slides: Q1 2026

May 6, 2026, 4:05 PM EDT - 6 weeks ago

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Sarepta Therapeutics Proxy statement: Proxy filing

Apr 22, 2026, 8:30 AM EDT - 2 months ago

Sarepta Therapeutics to Announce First Quarter 2026 Financial Results

2026-04-16T16:20:19.000Z - 2 months ago

Roche decision could hurt Sarepta in U.S., says H.C. Wainwright

2026-04-07T15:08:48.000Z - 2 months ago

Sarepta price target raised to $19 from $18 at RBC Capital

Mar 31, 2026, 4:05 PM EDT - 3 months ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-03-26T12:40:44.000Z - 3 months ago

Deutsche ups Sarepta target, says 35% stock rally overdone

2026-03-26T12:37:02.000Z - 3 months ago

Sarepta price target raised to $35 from $29 at Wedbush

2026-03-26T09:56:24.000Z - 3 months ago

Sarepta price target raised to $13 from $9 at Citi

2026-03-25T19:50:31.000Z - 3 months ago

Sarepta price target raised to $25 from $20 at Morgan Stanley

2026-03-25T14:10:14.000Z - 3 months ago

Sarepta initial siRNA data ‘thin and somewhat mixed,’ says Leerink

2026-03-25T13:55:34.000Z - 3 months ago

Sarepta early DM1 data ‘appear promising,’ says Oppenheimer

Mar 25, 2026, 8:30 AM EDT - 3 months ago

Sarepta Therapeutics Transcript: Study result

Mar 25, 2026, 8:30 AM EDT - 3 months ago

Sarepta Therapeutics Press release: Study result

Mar 25, 2026, 8:30 AM EDT - 3 months ago

Sarepta Therapeutics Slides: Study result

2026-03-25T12:10:47.000Z - 3 months ago

Sarepta announces first clinical data from pipeline targeting FSHD1, DM1

Mar 25, 2026, 8:05 AM EDT - 3 months ago

Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

Mar 24, 2026, 4:05 PM EDT - 3 months ago

Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

Mar 19, 2026, 8:30 AM EDT - 3 months ago

Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®

Mar 16, 2026, 8:33 AM EDT - 3 months ago

Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Mar 3, 2026, 1:50 PM EST - 4 months ago

Sarepta Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 27, 2026, 9:00 AM EST - 4 months ago

Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program

Feb 26, 2026, 8:30 AM EST - 4 months ago

Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress

Feb 26, 2026, 5:05 AM EST - 4 months ago

Sarepta Therapeutics CEO Ingram to retire by year end

Feb 25, 2026, 4:30 PM EST - 4 months ago

Sarepta Therapeutics Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:30 PM EST - 4 months ago

Sarepta Therapeutics Annual report: Q4 2025

Feb 25, 2026, 4:30 PM EST - 4 months ago

Sarepta Therapeutics Earnings release: Q4 2025

Feb 25, 2026, 4:30 PM EST - 4 months ago

Sarepta Therapeutics Slides: Q4 2025

Feb 25, 2026, 4:05 PM EST - 4 months ago

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

Feb 24, 2026, 9:07 AM EST - 4 months ago

Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

Feb 24, 2026, 8:30 AM EST - 4 months ago

Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Feb 11, 2026, 8:30 AM EST - 4 months ago

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

Feb 4, 2026, 8:30 AM EST - 5 months ago

Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease

Jan 26, 2026, 8:53 AM EST - 5 months ago

Sarepta Stock Rises on Positive 3-Year Study Results for Elevidys

Jan 26, 2026, 8:30 AM EST - 5 months ago

Sarepta Therapeutics Transcript: Study result

Jan 26, 2026, 8:30 AM EST - 5 months ago

Sarepta Therapeutics Press release: Study result

Jan 26, 2026, 8:30 AM EST - 5 months ago

Sarepta Therapeutics Slides: Study result

Jan 26, 2026, 8:10 AM EST - 5 months ago

Sarepta's Duchenne gene therapy helps maintain motor function, three-year data shows

Jan 26, 2026, 8:00 AM EST - 5 months ago

Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

Jan 23, 2026, 4:05 PM EST - 5 months ago

Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy

Jan 12, 2026, 12:00 PM EST - 5 months ago

Sarepta Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 12:00 PM EST - 5 months ago

Sarepta Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 11:58 AM EST - 5 months ago

Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

Jan 12, 2026, 9:30 AM EST - 5 months ago

Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty

Jan 7, 2026, 8:30 AM EST - 6 months ago

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's Disease

Jan 5, 2026, 8:30 AM EST - 6 months ago

Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 11, 2025, 7:00 AM EST - 6 months ago

Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027

Nov 25, 2025, 8:57 AM EST - 7 months ago

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Nov 24, 2025, 7:30 AM EST - 7 months ago

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

ARWR

Nov 24, 2025, 7:30 AM EST - 7 months ago

Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1

Nov 14, 2025, 2:54 PM EST - 7 months ago

Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information

Nov 14, 2025, 2:08 PM EST - 7 months ago

US FDA adds strongest warning to Sarepta gene therapy after fatal liver injuries

Nov 4, 2025, 9:55 AM EST - 8 months ago

Sarepta Therapeutics shares plunge after disappointing trial data

Nov 4, 2025, 6:20 AM EST - 8 months ago

Sarepta Stock Tumbles 40%. Why the Biotech's Shares Are Sinking.

Nov 4, 2025, 4:27 AM EST - 8 months ago

Sarepta slumps as gene therapy setback adds to drug pipeline woes

Nov 3, 2025, 6:26 PM EST - 8 months ago

Sarepta's stock plummets as disappointing trial data raise questions on DMD drug's success

Nov 3, 2025, 4:30 PM EST - 8 months ago

Sarepta Therapeutics Earnings Call Transcript: Q3 2025

Nov 3, 2025, 4:30 PM EST - 8 months ago

Sarepta Therapeutics Quarterly report: Q3 2025

Nov 3, 2025, 4:30 PM EST - 8 months ago

Sarepta Therapeutics Earnings release: Q3 2025

Nov 3, 2025, 4:30 PM EST - 8 months ago

Sarepta Therapeutics Slides: Q3 2025

Nov 3, 2025, 4:24 PM EST - 8 months ago

Sarepta's Duchenne gene therapy misses main goal in study

Nov 3, 2025, 4:05 PM EST - 8 months ago

Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE

Oct 27, 2025, 4:05 PM EDT - 8 months ago

Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results

Oct 23, 2025, 6:46 AM EDT - 8 months ago

Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF

BLSH DASH FLY IREN NEM OPEN QS

Oct 3, 2025, 8:30 AM EDT - 9 months ago

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress

Sep 5, 2025, 9:00 AM EDT - 10 months ago

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year

Aug 25, 2025, 3:11 AM EDT - 10 months ago

SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT

Aug 23, 2025, 7:08 AM EDT - 10 months ago

SRPT CLASS REMINDER: Suffer Losses on Your Sarepta Therapeutics, Inc. Investment? Contact BFA Law before the August 25 Court Deadline (NASDAQ:SRPT)

Aug 21, 2025, 7:00 AM EDT - 10 months ago

Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027

Fred_Sigma_Invest Jun. 24 at 4:48 PM

$SRPT

0 · Reply

Hoganknowsbest Jun. 24 at 4:42 PM

$SRPT need news to move it.

0 · Reply

Pipipopopipi Jun. 24 at 3:47 PM

$SRPT she’s holding extremely well. showing a lot of strength. Someone knows something😂😂😂😂

0 · Reply

Find_the_Cure Jun. 24 at 3:43 PM

$SRPT lunchtime manipulation because they can. Doug lets them.

0 · Reply

Find_the_Cure Jun. 24 at 2:41 PM

$SRPT bones: “he’s dead Jim”

0 · Reply

Fred_Sigma_Invest Jun. 24 at 2:40 PM

$SRPT You know it’s bad when not even @Thaigrlsrk is here pushing his lying, clownish BS.

1 · Reply

Pipipopopipi Jun. 24 at 2:30 PM

$SRPT markets moving up againg and srpt dives again. What a stock. in doug we trust. Easiest short on the market

0 · Reply

reggie_one Jun. 24 at 2:11 PM

$SRPT Up a few cents and the pumpers are all giddy thinking this will make them kazillionares following kims promises of 600 per share by end of year

0 · Reply

WeAreKangz Jun. 24 at 1:46 PM

$SRPT biotech higher highs sarepta lower lows lmao. Doug gets the short bus award of the year

1 · Reply

free2dream Jun. 24 at 1:36 PM

$SRPT WAKE THE FXCK UP WALL STREET ANALYST MORONS !

0 · Reply

Find_the_Cure Jun. 24 at 1:12 PM

$SRPT when is Doug going to be stepped down?!?

0 · Reply

Find_the_Cure Jun. 24 at 11:53 AM

$SRPT Don’t like the price? Just ask Doug the worthless CEO and short timer (and friend of the shorts) who promised that the price would recover. I don’t see any price recovery here until he is removed from the front office. The sooner the better… JMHO

0 · Reply